
Selecting initial therapy for COPD¹



Use one of two standardized tools to assess symptom severity:



Modified Medical Research Council (mMRC) dyspnea score

Or ask: "Do you walk slower than people of the same age because of breathlessness, or have to stop for breath on LEVEL ground?"




COPD Assessment test (CAT)

Assesses overall health, not just dyspnea

Significant symptoms are an mMRC ≥ 2 or a CAT score ≥ 10 .

*Establish exacerbation history: Exacerbations are discrete episodes of worsening symptoms (i.e., increased dyspnea, sputum volume, or purulence) over < 14 days that require intervention.

Escalating treatment based on symptoms or exacerbations



Medications in bottom row: Refer to pulmonologist if available.

Inhaler types by class

	Metered dose inhaler (MDI)	Dry powder inhaler (DPI)	Soft mist inhaler (SMI)	Nebulizers
Inhaler class Example inhalers and platforms	Aerosphere, HFA, RediHaler	Diskus, Ellipta, Pressair, RespiClick*	Respimat	nebulizers
LABA		√	√	√
LAMA		√	√	√
ICS	✓	✓		√
LABA + LAMA	✓	✓	√	
LABA + ICS	✓	✓		
LABA + LAMA + ICS	1	1		
Rescue inhalers	√	√	√	√
Tips for use	requires dexterity use a spacer to help with delivery	powder can be irritating requires inspiratory capacity	requires dexterity	requires a nebulizer machine

^{*}Platforms shown available in two or more inhalers.

ICS = inhaled corticosteroids; LABA = long-acting beta agonists; LAMA = long-acting muscarinic antagonists



Inhaler technique education

Videos from the American Lung Association to help teach patients about best use of devices.

(1) Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease*. 2025:1-202.







Balanced information for better care

These are general recommendations only; specific clinical decisions should be made by the treating clinician based on an individual patient's clinical condition. This material is provided by Alosa Health, a nonprofit organization which accepts no funding from any pharmaceutical company. It was supported by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania.

Copyright 2025 by Alosa Health. All rights reserved.

AH-001-0045 Apr 2025